Every Form 4 that Biohaven Ltd. (BHVN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BHVN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BHVN filings page.
Biohaven Ltd. (BHVN) reported that officer Kimberly Gentile, SVP, Clinical Operations, had a stock option grant reported in her name for 1,000 options to purchase Biohaven common shares at an exercise price of $12.34 per share, expiring September 15, 2036. The option was granted in connection with her son's employment and is held indirectly "By Son", with vesting in four equal installments on September 15 of 2026, 2027, 2028 and 2029, subject to his continuous service. Gentile disclaims beneficial ownership of all securities held by her son, and no Rule 10b5-1 trading plan is reported.
Biohaven Ltd. director Kishan Mehta received a grant of 68,693 stock options on April 28, 2026. Each option gives the right to buy one common share at an exercise price of $9.61 and expires on April 28, 2036.
According to the vesting terms, all 68,693 options will vest in full on the earlier of April 28, 2027 or the date of Biohaven’s 2027 Annual Meeting of Shareholders, provided Mehta continues to serve with the company through that vesting date.
Biohaven Ltd. director Gregory Bailey reported receiving a grant of stock options as part of his compensation. The award covers 68,693 stock options, each allowing him to buy one common share at an exercise price of $9.61 per share.
The options vest in full on the earlier of April 28, 2027 or the date of Biohaven’s 2027 Annual Meeting of Shareholders, as long as he continues serving the company until that vesting date. After this grant, he holds 68,693 options directly, and this filing does not show any open-market buying or selling of shares.
Biohaven Ltd. director Michael Thomas Heffernan received a grant of stock options on April 28, 2026. The award covers 68,693 options, each allowing him to buy one common share at an exercise price of $9.61. After this grant, he holds 68,693 options directly.
These options vest in full on the earlier of April 28, 2027 or the date of Biohaven’s 2027 Annual Meeting of Shareholders, as long as he continues serving the company through that date. The options expire on April 28, 2036. This is a compensation-related grant rather than an open-market share purchase or sale.
Biohaven Ltd. director Irina Antonijevic received a grant of stock options covering 68,693 common shares, with an exercise price of 9.61 per share. These options vest in full on the earlier of April 28, 2027 or the 2027 Annual Meeting of Shareholders, subject to her continuous service, and expire on April 28, 2036.
Biohaven Ltd. director John W. Childs reported a grant of stock options covering 68,693 Common Shares. The options have an exercise price of $9.61 per share, expire on April 28, 2036, and were received as a compensation award rather than an open‑market purchase.
These options will vest in full on the earlier of April 28, 2027 or the 2027 Annual Meeting of Shareholders, provided Childs continues serving the company through that date. Following this grant, he holds 68,693 stock options directly.
Biohaven Ltd. director Robert J. Hugin received a grant of stock options, giving him the right to buy 68,693 common shares at an exercise price of $9.61 per share. These options vest in full on the earlier of April 28, 2027 or the 2027 Annual Meeting of Shareholders, subject to his continuous service. After this award, he holds 68,693 stock options directly, with an expiration date of April 28, 2036.
Biohaven Ltd. director Julia P. Gregory received a grant of 68,693 stock options to buy Common Shares at an exercise price of $9.61 per share. The options expire on April 28, 2036 and represent compensation rather than an open-market purchase.
These options will vest in full on the earlier of April 28, 2027 or the date of Biohaven’s 2027 Annual Meeting of Shareholders, provided she continues serving the company through that vesting date. After this award, she holds 68,693 stock options directly.
Biohaven Ltd. director Kishan Mehta reported bona fide gift transfers of a total of 34,684 common shares on 2026-03-17. One transfer of 17,342 shares reduced his directly held stake to 5,320 common shares.
A separate 17,342-share transfer is shown as indirectly held by the “Kishen Mehta 21 Family Irrevocable Trust.” The trust is for the benefit of family members other than the reporting person, and Mehta disclaims beneficial ownership of the securities held by the trust.
Biohaven Ltd. director John W. Childs reported an amended insider transaction showing an indirect open‑market purchase of 28,400 Common Shares by the John W Childs 2013 Revocable Trust at a weighted average price of $30.4266 per share.
The amendment corrects an earlier filing that had allocated 3,400 purchased shares to a 2013 Charitable Remainder Trust and 25,000 shares to the revocable trust. It clarifies that all 28,400 shares were acquired through the revocable trust, with no shares acquired through the charitable remainder trust in this transaction.
Biohaven Ltd. Chief Financial Officer Matthew Buten reported an award of stock options on a Form 4. He acquired 175,000 stock options as a grant, bringing his directly owned derivative holdings in this award to 175,000 options. The options vest in four equal installments on February 27 of 2026, 2027, 2028 and 2029, as long as he continues serving the company on each vesting date. This is a compensation-related equity grant rather than an open-market stock purchase or sale.
Gentile Kimberly reported acquisition or exercise transactions in this Form 4 filing.
Biohaven Ltd. reported that senior vice president of clinical operations Kimberly Gentile received a grant of stock options covering 175,000 shares. The options were awarded on February 27, 2026 and will vest in four equal installments on February 27 of 2026, 2027, 2028 and 2029, conditioned on her continuous service with the company.
Biohaven Ltd. reported that its VP and Chief Accounting Officer, Clark George C., received a grant of stock options covering 50,000 shares of the company’s stock. The options have an exercise price of $0.00 per share, reflecting a compensatory award rather than a market purchase.
The options vest in four equal installments on February 27 of each year from 2026 through 2029, and each vesting tranche requires Clark George C. to remain continuously employed by Biohaven through the relevant vesting date.
Biohaven Ltd. Chief Scientific Officer Bruce Car received a grant of stock options on February 27, 2026. The award covers 175,000 stock options with an exercise price of $0.00 per share, giving him the right to buy Biohaven shares if he chooses to exercise in the future.
The options vest in four equal installments on February 27, 2026, 2027, 2028 and 2029, and each installment requires his continuous service with the company through the relevant vesting date. After this grant, he directly holds 175,000 derivative securities in the form of stock options.
Coric Vlad reported acquisition or exercise transactions in this Form 4 filing.
Biohaven Ltd. Chief Executive Officer Vlad Coric reported receiving a grant of stock options on February 27, 2026. The award covers 550,000 stock options with a stated price per share of $0.00, increasing his directly held option position to 550,000 derivative securities.
According to the footnote, the options vest in four equal installments on February 27, 2026, 2027, 2028 and 2029, and each vesting is conditioned on his continuous service with Biohaven on the relevant vesting date.
Biohaven Ltd. senior vice president of clinical operations Kimberly Gentile reported routine equity transactions tied to restricted share units. On January 5, 2026, 3,750 restricted share units converted into the same number of common shares at an exercise price of $0, increasing her directly held stake. To cover tax withholding on this vesting, 1,956 common shares were withheld by the company at a price of $9.93 per share, with no shares sold into the market. After these transactions, Gentile directly owned 99,557 common shares and held 7,500 restricted share units, which represent the right to receive additional common shares as future vesting dates are met.
Biohaven Ltd. Chief Financial Officer Matthew Buten reported equity award activity and related tax withholding on common shares. On January 5, 2026, 4,250 restricted share units were exercised at an effective price of $0, delivering the same number of common shares. To cover taxes due on this vesting, 2,594 common shares were withheld by Biohaven at a price of $9.93 per share, and no shares were sold into the market.
After these transactions, Buten directly beneficially owned 195,652 common shares, which includes 544 shares acquired through the Biohaven Employee Share Purchase Plan on May 31, 2025. He also held 8,500 restricted share units following the reported transaction, each representing the right to receive one common share, with the original 17,000-unit grant vesting in four annual installments through January 5, 2028, subject to continued service.
Biohaven Ltd. Chief Executive Officer and director Vlad Coric reported routine equity compensation activity. On January 5, 2026, 14,250 restricted share units vested and were converted into 14,250 common shares at $0 per share. On the same date, 7,430 common shares were withheld by Biohaven at $9.93 per share to cover tax obligations, and no shares were sold into the market.
Following these transactions, Coric directly holds 1,803,968 common shares and 28,500 restricted share units. Additional common shares are held indirectly through a family trust, a marital trust and a 401(k) plan. The family and marital trust positions are for the benefit of family members other than Coric, and he disclaims beneficial ownership of those securities.
Biohaven Ltd. Chief Scientific Officer Car Bruce reported equity award activity and updated holdings. On January 5, 2026, 4,750 restricted share units converted into an equal number of common shares at an exercise price of $0, reflecting a scheduled vesting from a prior grant.
To cover taxes on this vesting, 2,381 common shares were withheld by Biohaven at $9.93 per share rather than sold on the market. After these transactions, Car Bruce directly owns 7,715 common shares, which include 544 shares acquired through the company’s employee share purchase plan, and indirectly holds 30,000 common shares through an IRA. The original restricted share unit grant was 19,000 units awarded on January 5, 2025, vesting in four equal annual installments through 2028, with 9,500 units remaining outstanding after this vesting.
Biohaven Vice President and Chief Accounting Officer George C. Clark reported the vesting and conversion of 2,500 restricted share units into common shares on January 5, 2026. To satisfy taxes, 1,117 shares were withheld by the issuer at $9.93 per share rather than sold in the market. After these transactions, he owns 66,978 common shares directly and 20,000 common shares indirectly through an IRA. The RSUs are part of a 10,000-unit grant from January 5, 2025 that vests in four equal annual installments.
Biohaven Ltd. officer reports open-market share purchase. A vice president and Chief Accounting Officer of Biohaven Ltd. (BHVN) bought 17,000 common shares on 11/17/2025 at a weighted average price of $8.5159 per share through a series of trades within a narrow price range. After this transaction, the insider beneficially owns 20,000 common shares indirectly through an IRA and 65,595 shares directly, for a combined personal stake in the company that includes 544 shares acquired under the employee share purchase plan.
Biohaven Ltd. director reports a large share purchase. A company director filed a Form 4 disclosing the acquisition of 400,000 Biohaven common shares on 11/13/2025 in an underwritten public offering at a price of $7.5 per share. Following this transaction, the director beneficially owns 2,020,071 common shares in total, held directly.
Biohaven Ltd. (BHVN) reported an insider purchase by a director who indirectly acquired 3,333,333 common shares on 11/13/2025. The transaction was coded "P" for a purchase at a price of $7.50 per share and is described as common shares acquired in an underwritten public offering.
After this transaction, indirect beneficial ownership includes 5,653,904 common shares held by the John W Childs 2013 Revocable Trust, as well as additional indirect holdings of 4,096,512, 76,570, 25,291 and 24,452 common shares through various charitable remainder trusts.
Biohaven Ltd. director and CEO Vlad Coric reported purchasing additional common shares of BHVN on 11/13/2025 in an underwritten public offering. Two trusts associated with his family each acquired 333,333 common shares at $7.50 per share, one held by The Vlad Coric Family Trust and the other by The Vladimir Coric Marital Trust.
After these transactions, reported holdings include 1,195,275 common shares held by The Vlad Coric Family Trust, 740,546 common shares held by The Vladimir Coric Marital Trust, and 109,565 common shares in a 401(k) plan. An additional 1,797,148 common shares are reported as held directly. The report notes that the family trust shares are for the benefit of family members, that his spouse is trustee, and that Coric disclaims beneficial ownership of those trust-held securities. It also states that the direct balance includes 544 shares acquired through the Biohaven Employee Share Purchase Plan on May 30, 2025.